These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 38925586

  • 1. Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial.
    Yang S, Chen SS, Zhang CG, Zhou YL, Xiu M, Zhang P.
    Br J Clin Pharmacol; 2024 Oct; 90(10):2621-2629. PubMed ID: 38925586
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Huang W, Liu J, Zeng Y, Wu F, Li N, Chen K, Hong Y, Wang L, Zhen H, Lin L.
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY.
    Zhonghua Yi Xue Za Zhi; 2006 Dec 26; 86(48):3414-9. PubMed ID: 17313855
    [Abstract] [Full Text] [Related]

  • 4. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
    Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, Qin Y, Li B, Huang DZ, Zhang CG, Sun Y.
    Ai Zheng; 2006 Apr 26; 25(4):495-500. PubMed ID: 16613688
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
    Ji X, Xu L, Pan P, Xu Z, Wang A, Li Y.
    Thorac Cancer; 2022 Jan 26; 13(1):117-125. PubMed ID: 34791805
    [Abstract] [Full Text] [Related]

  • 6. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Zhou C, Huang Y, Wang D, An C, Zhou F, Li Y, Chen G, Wu C, He J, Wu G, Song X, Gao J, Liu W, Li B, Shi J, Huang C, Yu J, Feng J, Yue H, Shi M, Xia J.
    Clin Lung Cancer; 2016 Mar 26; 17(2):119-27. PubMed ID: 26781346
    [Abstract] [Full Text] [Related]

  • 7. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Xie J, Cao J, Wang JF, Zhang BH, Zeng XH, Zheng H, Zhang Y, Cai L, Wu YD, Yao Q, Zhao XC, Mao WD, Jiang AM, Chen SS, Yang SE, Wang SS, Wang JH, Pan YY, Ren BY, Chen YJ, Ouyang LZ, Lei KJ, Gao JH, Huang WH, Huang Z, Shou T, He YL, Cheng J, Sun Y, Li WM, Cui SD, Wang X, Rao ZG, Ma H, Liu W, Wu XY, Shen WX, Cao FL, Xiao ZM, Wu B, Tian SY, Meng D, Shen P, Wang BY, Wang Z, Zhang J, Wang L, Hu XC.
    Breast Cancer Res Treat; 2018 Apr 26; 168(2):389-399. PubMed ID: 29230663
    [Abstract] [Full Text] [Related]

  • 8. Pegylated recombinant human granulocyte colony-stimulating factor for primary prophylaxis of neutropenia in patients with cervical cancer receiving concurrent chemoradiotherapy: a prospective study.
    You J, Yuan Y, Gu X, Wang W, Li X.
    BMC Cancer; 2024 Jul 12; 24(1):833. PubMed ID: 38997665
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S, Shi YK, Liu P, Han XH, He XH, Cai YM, Chen ZM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun 12; 28(3):339-44. PubMed ID: 16900629
    [Abstract] [Full Text] [Related]

  • 10. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
    Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q, Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang S, Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y, Chen L.
    Zhonghua Zhong Liu Za Zhi; 2016 Jan 12; 38(1):23-7. PubMed ID: 26796802
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
    Jiang Y, Zhang J, Zhong J, Liao H, Zhang J, Liu Y, Liang Y, Li H.
    BMC Cancer; 2023 Jul 26; 23(1):702. PubMed ID: 37495949
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
    Hu C, Ji B, Hu X, Yang C, Sun W, Zhao X, Li L, Li X, Zhang L.
    Clin Pharmacol Drug Dev; 2021 Mar 26; 10(3):291-298. PubMed ID: 32567217
    [Abstract] [Full Text] [Related]

  • 13. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).
    Huang X, Li S, Shi W, Wang Y, Wan X, He J, Xu Y, Zhang W, Shi X, Chen R, Xu L, Zha X, Wang J.
    Br J Clin Pharmacol; 2023 Jan 26; 89(1):372-379. PubMed ID: 36001055
    [Abstract] [Full Text] [Related]

  • 14. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
    Gladkov O, Moiseyenko V, Bondarenko IN, Shparyk Y, Barash S, Adar L, Avisar N.
    Oncologist; 2016 Jan 26; 21(1):7-15. PubMed ID: 26668251
    [Abstract] [Full Text] [Related]

  • 15. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
    Schwartzberg LS, Bhat G, Peguero J, Agajanian R, Bharadwaj JS, Restrepo A, Hlalah O, Mehmi I, Chawla S, Hasal SJ, Yang Z, Cobb PW.
    Oncologist; 2020 Aug 26; 25(8):e1233-e1241. PubMed ID: 32476162
    [Abstract] [Full Text] [Related]

  • 16. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
    Zou D, Guo M, Zhou Q.
    BMC Cancer; 2021 Jun 02; 21(1):661. PubMed ID: 34078317
    [Abstract] [Full Text] [Related]

  • 17. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
    Lee KH, Kim JY, Lee MH, Han HS, Lim JH, Park KU, Park IH, Cho EK, Yoon SY, Kim JH, Choi IS, Park JH, Choi YJ, Kim HJ, Jung KH, Kim SY, Oh DY, Im SA.
    Support Care Cancer; 2016 Apr 02; 24(4):1709-17. PubMed ID: 26423618
    [Abstract] [Full Text] [Related]

  • 18. [The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy].
    Zhang JY, Liu YX, Wang H, Mi L, Song GH, Jiang HF, Yan Y, Shao B, Kong WY, Zhang RY, Ran R, Liu XR, Wang J, Lin YT, Li HP.
    Zhonghua Yi Xue Za Zhi; 2018 Sep 11; 98(34):2718-2721. PubMed ID: 30220167
    [Abstract] [Full Text] [Related]

  • 19. [Application of pegylated recombinant human granulocyte colony-stimulating factor to prevent chemotherapy-induced neutropenia in patients with lymphoma: a prospective, multicenter, open-label clinical trial].
    Huang HQ, Bai B, Gao YH, Zou DH, Zou SH, Tan H, Song YP, Li ZY, Jin J, Li W, Su H, Gong YP, Zhong MZ, Shuang YR, Zhu J, Zhang JQ, Cai Z, Teng QL, Sun WJ, Yang Y, Xia ZJ, Chen HL, Hua LM, Bao YY, Wu N.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct 14; 38(10):825-830. PubMed ID: 29166732
    [Abstract] [Full Text] [Related]

  • 20. [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China].
    Xia W, Wang SS, Hu H, Zhao FL, Xu F, Hong RX, Jiang KK, Yuan ZY, Shi YX, Zhao K, Huang JJ, Xue C, Bi XW, Lu QY, An X, Zhang JM.
    Zhonghua Zhong Liu Za Zhi; 2020 Oct 23; 42(10):861-867. PubMed ID: 33113628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.